Tracers / [131I]I-Tyr-d-peptide-PEG11-Tz

[131I]I-Tyr-d-peptide-PEG11-Tz

Also written as [I-131]I-Tyr-d-peptide-PEG11-Tz
Radionuclide
I-131 t½ 11549 min
Modality
Therapy
Production route
Stage
Reported once
Syntheses indexed
1

What it is

Compound class
Tetrazine-bearing peptide probe (Tyr-d-peptide-PEG11-Tz) for pretargeted radioimmunotherapy
Target / mechanism
Click-to-chelate pretargeting via IEDDA reaction between tetrazine probe and TCO-Pertuzumab bound to HER2 PMID 42592442
Clinical application
Pretargeted radionuclide therapy for HER2-positive tumors using tetrazine probe following TCO-Pertuzumab pretargeting PMID 42592442
Theranostic pair

Regulatory status

FDA
EMA (centralised)
Other approvals
Brand names

Clinical use

Typical injected activity
Uptake time

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
Manual synthesisHPLCgreater than 95%approximately 99%Tyr-d-peptide-PEG11-Tz42592442
2026 Acta Pharm Sin B
For radiolabelling, 60 μg of Tyr-d-peptide-PEG11-Tz in 0.01 mol/L PBS and 105-120 MBq Na131I solution were added to an iodogen tube. The reaction occurred at 20 °C for 15 min — The radiochemical yield of [131I]I-Tyr-d-peptide-PEG11-Tz was greater than 95%

Need this precursor?We can point you to suppliers for [131I]I-Tyr-d-peptide-PEG11-Tz, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 42592442. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 42592442: '60 μg of Tyr-d-peptide-PEG11-Tz in 0.01 mol/L PBS'.